This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 99/7/723    most recent 01.RES.0000244015.10655.3fv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cui, R. Articles by Brasier, A. R. Search for Related Content PubMed PubMed Citation Articles by Cui, R. Articles by Brasier, A. R. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Related Collections ACE/Angiotension receptors Cell signalling/signal transduction Gene expression Genomics Growth factors/cytokines

(Circulation Research. 2006;99:723.)
© 2006 American Heart Association, Inc.

Molecular Medicine

RhoA Mediates Angiotensin II–Induced Phospho-Ser536 Nuclear Factor B/RelA Subunit Exchange on the Interleukin-6 Promoter in VSMCs

Ruwen Cui, Brian Tieu, Adrian Recinos, Ronald G. Tilton, Allan R. Brasier

From the Department of Medicine (R.C., B.T., A.R., R.G.T., A.R.B.), Department of Biochemistry and Molecular Biology (B.T.), Stark Diabetes Center (R.G.T.), and Sealy Center for Molecular Medicine (A.R.B.), University of Texas Medical Branch, Galveston.

Correspondence to Allan R. Brasier, Division of Endocrinology, MRB 8.128, University of Texas Medical Branch, 301 University Blvd, Galveston, TX 77555-1060. Email arbrasie{at}utmb.edu

The vasoconstrictor angiotensin II (Ang II) accelerates atherosclerosis by inducing vascular gene expression programs, producing monocyte recruitment, and vascular remodeling. In vascular smooth muscle cells (VSMCs), Ang II signaling activates interleukin (IL)-6 expression, a cytokine producing acute-phase inflammation, mediated by the transcription factor nuclear factor B (NF-B). The classical NF-B activation pathway involves cytoplasmic-to-nuclear translocation of the potent RelA transactivating subunit; however, because nuclear RelA is present in VSMCs, the mechanism by which NF-B activity is controlled is incompletely understood. In this study, we focus on early activation steps controlling RelA activation. Although Ang II only weakly induces 1.5-fold RelA nuclear translocation, RelA is nevertheless required because short interfering RNA–mediated RelA knockdown inhibits inducible IL-6 expression. We find instead that Ang II stimulation rapidly induces RelA phosphorylation at serine residue 536, a critical regulatory site in its transactivating domain. Chromatin immunoprecipitation assays indicate no significant changes in total RelA binding to the native IL-6 promoter, but an apparent increase in fractional binding of phospho-Ser536 RelA. Inactivation of RhoA by treatment with Clostridium botulinum exoenzyme C3 exotoxin or expression of dominant negative RhoA blocks Ang II–inducible RelA Ser536 phosphorylation and IL-6 expression. Finally, enhanced phospho-Ser536 RelA formation in the aortae of rats chronically infused with Ang II was observed. Together, these data indicate a novel mechanism for Ang II–induced NF-B activation in VSMCs, mediated by RhoA-induced phospho-Ser536 RelA formation, IL-6 expression, and vascular inflammation.

Key Words: RhoA • nuclear factor B • vascular inflammation • atherosclerosis

This article has been cited by other articles:

				K. Takeda, T. Ichiki, E. Narabayashi, K. Inanaga, R. Miyazaki, T. Hashimoto, H. Matsuura, J. Ikeda, T. Miyata, and K. Sunagawa Inhibition of Prolyl Hydroxylase Domain-Containing Protein Suppressed Lipopolysaccharide-Induced TNF-{alpha} Expression Arterioscler Thromb Vasc Biol, December 1, 2009; 29(12): 2132 - 2137. [Abstract] [Full Text] [PDF]

				M. Jamaluddin, B. Tian, I. Boldogh, R. P. Garofalo, and A. R. Brasier Respiratory Syncytial Virus Infection Induces a Reactive Oxygen Species-MSK1-Phospho-Ser-276 RelA Pathway Required for Cytokine Expression J. Virol., October 15, 2009; 83(20): 10605 - 10615. [Abstract] [Full Text] [PDF]

				C. Pellieux, C. Montessuit, I. Papageorgiou, and R. Lerch Angiotensin II downregulates the fatty acid oxidation pathway in adult rat cardiomyocytes via release of tumour necrosis factor-{alpha} Cardiovasc Res, May 1, 2009; 82(2): 341 - 350. [Abstract] [Full Text] [PDF]

				P. Holvoet and P. Sinnaeve Angio-Associated Migratory Cell Protein and Smooth Muscle Cell Migration in Development of Restenosis and Atherosclerosis J. Am. Coll. Cardiol., July 22, 2008; 52(4): 312 - 314. [Full Text] [PDF]

				D. E. Nowak, B. Tian, M. Jamaluddin, I. Boldogh, L. A. Vergara, S. Choudhary, and A. R. Brasier RelA Ser276 Phosphorylation Is Required for Activation of a Subset of NF-{kappa}B-Dependent Genes by Recruiting Cyclin-Dependent Kinase 9/Cyclin T1 Complexes Mol. Cell. Biol., June 1, 2008; 28(11): 3623 - 3638. [Abstract] [Full Text] [PDF]

				P. Y. Mong, C. Petrulio, H. L. Kaufman, and Q. Wang Activation of Rho Kinase by TNF-{alpha} Is Required for JNK Activation in Human Pulmonary Microvascular Endothelial Cells J. Immunol., January 1, 2008; 180(1): 550 - 558. [Abstract] [Full Text] [PDF]

				S. Choudhary, M. Lu, R. Cui, and A. R. Brasier Involvement of a Novel Rac/RhoA Guanosine Triphosphatase-Nuclear Factor-{kappa}B Inducing Kinase Signaling Pathway Mediating Angiotensin II-Induced RelA Transactivation Mol. Endocrinol., September 1, 2007; 21(9): 2203 - 2217. [Abstract] [Full Text] [PDF]

				H. Chen and B. L. Firestein RhoA Regulates Dendrite Branching in Hippocampal Neurons by Decreasing Cypin Protein Levels J. Neurosci., August 1, 2007; 27(31): 8378 - 8386. [Abstract] [Full Text] [PDF]

				S. Sahar, M. A. Reddy, C. Wong, L. Meng, M. Wang, and R. Natarajan Cooperation of SRC-1 and p300 With NF-{kappa}B and CREB in Angiotensin II-Induced IL-6 Expression in Vascular Smooth Muscle Cells Arterioscler Thromb Vasc Biol, July 1, 2007; 27(7): 1528 - 1534. [Abstract] [Full Text] [PDF]

				J. Ruef, M. Browatzki, C. A. Pfeiffer, J. Schmidt, and R. Kranzhofer Angiotensin II promotes the inflammatory response to CD40 ligation via TRAF-2 Vascular Medicine, February 1, 2007; 12(1): 23 - 27. [Abstract] [PDF]